HLS Therapeutics Inc - Asset Resilience Ratio
HLS Therapeutics Inc (HLS) has an Asset Resilience Ratio of 10.13% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check HLS Therapeutics Inc (HLS) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2022)
This chart shows how HLS Therapeutics Inc's Asset Resilience Ratio has changed over time. See HLS equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down HLS Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HLS Therapeutics Inc (HLS) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$21.81 Million | 10.13% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$21.81 Million | 10.13% |
Asset Resilience Insights
- Moderate Liquidity: HLS Therapeutics Inc has 10.13% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
HLS Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare HLS Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for HLS Therapeutics Inc (2001–2022)
The table below shows the annual Asset Resilience Ratio data for HLS Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 8.58% | CA$20.72 Million ≈ $14.99 Million |
CA$241.65 Million ≈ $174.81 Million |
+0.90pp |
| 2021-12-31 | 7.68% | CA$21.18 Million ≈ $15.32 Million |
CA$275.90 Million ≈ $199.59 Million |
+0.89pp |
| 2020-12-31 | 6.78% | CA$20.61 Million ≈ $14.91 Million |
CA$303.91 Million ≈ $219.84 Million |
-7.94pp |
| 2019-12-31 | 14.73% | CA$47.08 Million ≈ $34.06 Million |
CA$319.67 Million ≈ $231.25 Million |
+11.16pp |
| 2018-12-31 | 3.57% | CA$10.93 Million ≈ $7.91 Million |
CA$306.43 Million ≈ $221.66 Million |
-5.85pp |
| 2017-12-31 | 9.42% | CA$36.22 Million ≈ $26.20 Million |
CA$384.65 Million ≈ $278.25 Million |
+9.05pp |
| 2003-12-31 | 0.37% | CA$153.46K ≈ $111.01K |
CA$41.49 Million ≈ $30.01 Million |
-0.24pp |
| 2002-12-31 | 0.61% | CA$173.60K ≈ $125.58K |
CA$28.64 Million ≈ $20.72 Million |
+0.04pp |
| 2001-12-31 | 0.57% | CA$171.84K ≈ $124.31K |
CA$30.37 Million ≈ $21.97 Million |
-- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more